MR guided radiotherapy for Malignancies

Phase-Based Progress Estimates
Cross Cancer Institute, Edmonton, Canada
MR guided radiotherapy - Device
All Sexes
What conditions do you have?

Study Summary

Cancers are often treated with external beam radiotherapy. Current radiotherapy treatments are performed using computed tomography (also known as CT) scans which may not always clearly identify the cancer. In some instances, magnetic resonance imaging (MRI) may be able to better identify cancers. Therefore, efforts are currently underway to use the MRI scans to improve radiotherapy treatments or eventually even use radiotherapy equipment that only uses MRI scans to guide treatments. This new technology that will only use MRI scans to guide treatments is called the Linac-MR (linear accelerator with an MRI). This new Linac-MR is a unique innovation at the Cross Cancer Institute, with theoretical advantages over other Linac-MR machines that are being tested elsewhere in the world. This feasibility study is being done as a first step in clinical development of the Linac-MR, as this new technology has to be tested to see if it is acceptable to both doctors and participants. The purpose of this Phase I/II study is (1) to verify treatment completion as intended and scheduled the oncology team, and (2) to evaluate treatment effects, including any expected or unexpected radiation side effects and cancer response to radiation. This study will allow the researchers at the Cross Cancer Institute to develop this technology further by conducting additional studies to take advantage of MRI scanning on tumor tracking during radiation treatments.

Treatment Effectiveness

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: Up to 5 years after completion of treatment

1 year post treatment
Overall treatment planning time
Overall treatment time
Quantify the patient experience on the Linac-MR
6 months post treatment
Incidence of acute toxicity
Approximately 26 months
Proportion of participants that complete a course of external beam radiotherapy with the Alberta linac-MR P3 system
Year 5
Disease-free survival
Overall survival
Time to local control
Year 5
Incidence of late toxicity

Trial Safety

Trial Design

1 Treatment Group

MR guided radiotherapy
1 of 1
Experimental Treatment

112 Total Participants · 1 Treatment Group

Primary Treatment: MR guided radiotherapy · No Placebo Group · Phase 1 & 2

MR guided radiotherapy
Experimental Group · 1 Intervention: MR guided radiotherapy · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years after completion of treatment
Closest Location: Cross Cancer Institute · Edmonton, Canada
Photo of Edmonton 1Photo of Edmonton 2Photo of Edmonton 3
2011First Recorded Clinical Trial
14 TrialsResearching Malignancies
405 CompletedClinical Trials

Who is running the clinical trial?

AHS Cancer Control AlbertaLead Sponsor
176 Previous Clinical Trials
35,868 Total Patients Enrolled
5 Trials studying Malignancies
529 Patients Enrolled for Malignancies
Nawaid Usmani, MDPrincipal InvestigatorCross Cancer Institute, Alberta Health Services
3 Previous Clinical Trials
504 Total Patients Enrolled
1 Trials studying Malignancies
100 Patients Enrolled for Malignancies

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have access to the clinic for follow-up.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.